271. Ankylosing spondylitis Clinical trials / Disease details
Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04839315 (ClinicalTrials.gov) | February 15, 2021 | 5/4/2021 | COVID-19 Vaccination in Rheumatic Disease Patients | Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases | Systemic Lupus Erythematosus;Sjogren's Syndrome;Inflammatory Myositis;Psoriatic Arthritis;Gout;Ankylosing Spondylitis;Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis);Osteoarthritis | Biological: mRNA COVD19 vaccine | Mayo Clinic | NULL | Recruiting | 18 Years | N/A | All | 100 | Early Phase 1 | United States |